- Home
- DTSS vs MTVA Comparison
DTSS vs MTVA Comparison
Compare DTSS & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- MTVA
- Stock Information
- Founded
- DTSS 2014
- MTVA 2014
- Country
- DTSS China
- MTVA United States
- Employees
- DTSS N/A
- MTVA N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- MTVA
- Sector
- DTSS Technology
- MTVA
- Exchange
- DTSS Nasdaq
- MTVA NYSE
- Market Cap
- DTSS 14.2M
- MTVA 13.6M
- IPO Year
- DTSS N/A
- MTVA N/A
- Fundamental
- Price
- DTSS $2.14
- MTVA $1.54
- Analyst Decision
- DTSS
- MTVA Strong Buy
- Analyst Count
- DTSS 0
- MTVA 1
- Target Price
- DTSS N/A
- MTVA $12.00
- AVG Volume (30 Days)
- DTSS 63.5K
- MTVA 21.0K
- Earning Date
- DTSS 05-12-2025
- MTVA 05-08-2025
- Dividend Yield
- DTSS N/A
- MTVA N/A
- EPS Growth
- DTSS N/A
- MTVA N/A
- EPS
- DTSS N/A
- MTVA N/A
- Revenue
- DTSS $47,284,153.00
- MTVA N/A
- Revenue This Year
- DTSS N/A
- MTVA N/A
- Revenue Next Year
- DTSS N/A
- MTVA N/A
- P/E Ratio
- DTSS N/A
- MTVA N/A
- Revenue Growth
- DTSS 117.51
- MTVA N/A
- 52 Week Low
- DTSS $1.65
- MTVA $1.29
- 52 Week High
- DTSS $9.78
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- DTSS 46.85
- MTVA N/A
- Support Level
- DTSS $2.14
- MTVA N/A
- Resistance Level
- DTSS $2.44
- MTVA N/A
- Average True Range (ATR)
- DTSS 0.14
- MTVA 0.00
- MACD
- DTSS -0.00
- MTVA 0.00
- Stochastic Oscillator
- DTSS 12.50
- MTVA 0.00
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.